How Many Months of Wegovy to Lose Weight: A Comprehensive Guide

Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The pivotal Wegovy weight-management trials measured their primary results at 68 weeks — about 15 and a half months — and the newer high-dose trials measured at 72 weeks, roughly 16 and a half months. That is the honest answer to "how many months": the evidence base behind the label was built on a year and a half of continuous treatment, not on a three-month window. Weight comes off gradually and unevenly across that period, a meaningful share of it arrives in the first few months, and the trials that stopped treatment early showed exactly what happens next. The Wegovy prescribing information (revised 06/2026) is specific about all of it.

The Trials Were Built Around 68 and 72 Weeks

Section 14.2 of the Wegovy label describes the design: efficacy for weight reduction and long-term maintenance was studied in three 68-week randomized, double-blind, placebo-controlled trials, one 68-week placebo-withdrawal trial, one 68-week trial comparing two doses against placebo, and two 72-week trials comparing two doses against placebo. The oral formulation was studied in a separate 64-week trial.

Those are not arbitrary numbers. They were chosen because body weight does not plateau quickly on a GLP-1 receptor agonist, and a shorter trial would have measured an incomplete curve. Anyone asking how many months to expect is really asking where on that curve they will be at a given point — and the label answers by reporting where the whole population landed at the end.

The Escalation Period Is Part of the Timeline

A large portion of the first few months is spent reaching the maintenance dose, not sitting at it. In the label's Studies 2, 3, and 4, Wegovy or matching placebo "was escalated to 2.4 mg subcutaneous injection weekly during a 16-week period followed by 52 weeks on maintenance dose." In the two 72-week high-dose trials, escalation ran over 20 weeks before 52 weeks of maintenance. In one trial, the escalation run-in lasted 20 weeks before patients were randomized at all.

This is why month-three expectations so often disappoint. In the trial populations, month three was still inside the ramp. The comparison people make against a friend's results at week 12 is frequently a comparison between two different points on the escalation schedule. Your own schedule is set by your prescriber and stated on your pharmacy label — it is not something to infer from an article or from someone else's experience.

What 68 Weeks Actually Produced

In the label's Study 2 — the 68-week trial that enrolled 1,961 adults with obesity or overweight with a comorbidity, published as STEP 1 in the New England Journal of Medicine — the least-squares mean change in body weight at week 68 was −14.9% with Wegovy 2.4 mg versus −2.4% with placebo, a treatment difference of −12.4%. Mean baseline weight was about 105 kg in both arms.

The responder analysis is more informative than the average for most readers. At week 68, 83.5% of Wegovy-treated patients lost at least 5% of body weight versus 31.1% on placebo; 66.1% lost at least 10% versus 12%; 47.9% lost at least 15% versus 4.8%; and 30.2% lost at least 20% versus 1.7%. Roughly one in six did not reach the 5% threshold at all. A range that wide is the real answer to "how much, by when" — the mean describes the group, not you.

Diabetes Status Changes the Curve

The label's Study 3 ran the same 68-week design in 807 adults who had type 2 diabetes alongside obesity or overweight. Results were meaningfully smaller: −9.6% with Wegovy versus −3.4% with placebo, a −6.2% treatment difference, with 67.4% reaching 5% loss and 44.5% reaching 10%.

Same drug, same dose, same duration, materially different outcome — because the underlying metabolic context differs. Study 4, which combined Wegovy with intensive lifestyle therapy including an 8-week low-calorie diet, reported −16% versus −5.7%. The month count is identical across all three; the results are not.

The Newer 72-Week Data at the Higher Maximum

Wegovy's labeled maximum dosage for weight reduction in adults is now 7.2 mg once weekly, reached only after tolerating 2.4 mg. Study 8 was a 72-week trial in 1,407 adults with obesity, excluding type 2 diabetes, randomized 5:1:1 to 7.2 mg, 2.4 mg, or placebo. Mean baseline weight was 113 kg and mean BMI 39.9 kg/m².

At week 72, mean change from baseline was −18.8% at 7.2 mg, −15.5% at 2.4 mg, and −3.9% with placebo. The difference between the two active doses was −3.3%. Nearly 80% of the 7.2 mg group lost at least 10% and 45.5% lost at least 20%. Also worth noting: 5.4% of the 7.2 mg group permanently discontinued because of adverse reactions, versus 1% on placebo. More time and a higher dose produced more weight loss, and also more discontinuation.

What Happens When the Months Stop

The most useful trial for anyone thinking in months is the withdrawal design, Study 5 in the label, published as STEP 4 in JAMA. Patients escalated to 2.4 mg over a 20-week run-in, then were randomized either to continue or to switch to placebo for the remaining 48 weeks.

From week 20 to week 68, the continuation group lost a further 7.9% of body weight. The group switched to placebo gained 6.9% — a 14.8% difference between staying and stopping. This reframes the question entirely. Obesity is managed on the label as a chronic condition, and the label describes Wegovy's purpose as reducing excess body weight "and maintain weight reduction long term." The trials do not describe a course of treatment with a finish line; they describe ongoing therapy whose effect reverses when it ends.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

How many months did the Wegovy trials run?

The main weight-management trials in the Wegovy label ran 68 weeks, which is about 15 and a half months. The two newer high-dose trials, Studies 8 and 9, ran 72 weeks, roughly 16 and a half months. The trial of Wegovy tablets ran 64 weeks. Each of these included a dose-escalation period of 16 to 20 weeks at the start, followed by 52 weeks at the maintenance dosage before the primary endpoint was measured.

How much weight did people lose at 68 weeks?

In the label's Study 2, which enrolled 1,961 adults with obesity or overweight with a comorbidity, mean change in body weight at week 68 was −14.9% with Wegovy 2.4 mg versus −2.4% with placebo. Within that trial, 83.5% of treated patients lost at least 5% of body weight, 66.1% lost at least 10%, 47.9% lost at least 15%, and 30.2% lost at least 20%. The spread across individuals was wide.

Why do results seem slow in the first two or three months?

Because in the trials, the first 16 to 20 weeks were the dose-escalation period rather than the maintenance period. The primary endpoints were measured after 52 additional weeks at the maintenance dosage. Comparing your month-three result to someone else's is often comparing two different points on two different escalation schedules. Your own schedule is set by your prescriber and stated on your pharmacy label.

Does having type 2 diabetes change the timeline?

It changed the magnitude in the trials rather than the duration. The label's Study 3 used the same 68-week design in 807 adults with type 2 diabetes plus obesity or overweight and reported −9.6% with Wegovy versus −3.4% with placebo, compared with −14.9% versus −2.4% in the non-diabetes trial. Same drug, same duration, smaller average result. Discuss what that means for your situation with your prescriber.

What happens if I stop after several months?

The label's Study 5 tested exactly that. After a 20-week escalation run-in, patients either continued Wegovy or switched to placebo for 48 weeks. Those who continued lost a further 7.9% of body weight; those switched to placebo gained 6.9%, a difference of 14.8 percentage points. The label frames the indication as reducing excess body weight and maintaining that reduction long term, which reflects ongoing rather than time-limited therapy.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.